Hoechst Marion: Operating margin Zooms - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Hoechst Marion: Operating margin Zooms

Jul 30, 2001

Hoechst Marion Roussel Ltd (HMR) has posted a PBT of Rs 215 m, a rise of 47% inspite of 7% reduction in turnover. This rise was on the back of an 810 basis points improvement in operating profit margins of the company. The rise in operating margins was due to company's focus on strategic products, better efficiencies and reduction in operating expenses.

(Rs m)2QFY012QFY02Change
Sales 1,300 1,212 -6.8%
Other Income 19 13 -31.6%
Expenditure 1,132 969 -14.4%
Operating Profit (EBDIT) 168 243 44.6%
Operating Profit Margin (%)12.9%20.0%55.1%
Interest 13 4 -69.2%
Depreciation 28 37 32.1%
Profit before Tax 146 215 47.3%
Extraordinary Expenses (VRS) (25) (45)80.0%
Tax 44 48 9.1%
Profit after Tax/(Loss) 77 122 58.4%
Net profit margin (%)5.9%10.1% 
No. of Shares (eoy) (m) 23 23  
Diluted Earnings per share*13.421.2 
P/E (at current price) 19.3  
(*- annualised)   

The company's product portfolio now includes a rather unique combination of old, mature brands as well as new products, which have met with remarkable success. Major strategic brands of the company viz Cardace (69 %), Allegra (26%) and Amaryl (58%) continued to grow at a healthy rate. Other mature brands of the company seem to have maintained their revenue contribution. While domestic sales as a whole has remained flat, exports have grown by 19%.

The company's rationalisation of product portfolio in recent years has helped in reducing the DPCO exposure from around 60% to around 35% currently. Some of the strong brands from the company's stable like Avil, Daonil, Soframycin, Novalgin however, continue to be under DPCO coverage.

At the current market price of Rs 410, the stock is trading at 15 times its expected earnings for FY02. The growth in the current year is expected to be fuelled by latest product introductions.The triggers for the stock in the near term are expected outsourcing by the parent company 6-8 months down the line, growth in strategic new products, further introduction of new products and expected dilution of DPCO. However, slowdown in topline is a cause of concern. While the strategic products have recorded good growth rates, it has slowed down compared to 1QFY02. Further, though the company currently has been able to command premium prices for its strategic products till date, it might face stiff price competition from domestic players. Thus, the operating margins might witness a downturn as product portfolio of the company matures.

Equitymaster requests your view! Post a comment on "Hoechst Marion: Operating margin Zooms". Click here!

  

More Views on News

SANOFI INDIA 2019-20 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SANOFI INDIA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 7, 2021 10:46 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ADCOCK INGRAM COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS